Journal article
Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist
Abstract
BackgroundGonadotrophin releasing hormone (GnRH) agonists and antagonists reduce testosterone levels for the treatment of advanced and metastatic prostate cancer. Androgen deprivation therapy (ADT) is associated with increased risk of cardiovascular (CV) events and CV disease (CVD), especially in patients with preexisting CVD treated with GnRH agonists. Here, we investigated the potential relationship between serum levels of the cardiac …
Authors
Margel D; Ber Y; Peer A; Shavit-Grievink L; Pinthus JH; Witberg G; Baniel J; Kedar D; Rosenbaum E
Journal
Prostate Cancer and Prostatic Diseases, Vol. 24, No. 1, pp. 177–185
Publisher
Springer Nature
Publication Date
March 2021
DOI
10.1038/s41391-020-0264-9
ISSN
1365-7852